drugset / Trial / NCT03144804
A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a drug as a possible treatment for p53 mutant metastatic colorectal cancer. The drug involved in this study is: -Lamivudine
Timeline
- Start
- 2017-10-31
- Primary completion
- 2020-03-26
- Completion
- 2022-09-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lamivudine | Other / unclassified | — | Oral |